Chapter 1 – Principles of Pharmacology
,(From Psychopharmacology: Drugs, the Brain, and Behavior, 4th Edition by
Meyer & Quenzer)
Each question has:
A clinical or research-oriented scenario
Answer choices (A–D)
✅ Correct Answer clearly labeled
Deep rationale for correct & incorrect options
Chapter 1 – Principles of Pharmacology: 28 Extra-Advanced MCQs
1.
A pharmaceutical company is developing a new antipsychotic medication.
During initial studies, they observe that increasing the dose beyond a certain
point no longer improves therapeutic effect but increases side effects. What
pharmacological principle does this illustrate?
A. First-pass metabolism
B. Dose-response curve plateau
C. Bioavailability limitation
D. Half-life extension
✅ Correct Answer: B
Rationale: The dose-response curve plateau represents the maximal efficacy
of a drug. Beyond this point, further increasing the dose does not increase
therapeutic effect but often increases adverse effects. This is a core concept
in pharmacodynamics.
A: First-pass metabolism involves drug metabolism in the liver before
reaching systemic circulation.
C: Bioavailability refers to the proportion of drug entering circulation,
not dose-effect limits.
, D: Half-life relates to drug elimination, not efficacy limits.
2.
A drug is administered orally, but only 40% reaches systemic circulation due
to extensive metabolism in the liver before entering the bloodstream. This
phenomenon is known as:
A. Blood-brain barrier filtration
B. First-pass effect
C. Renal clearance
D. Bioequivalence failure
✅ Correct Answer: B
Rationale: The first-pass effect refers to the metabolism of a drug in the liver
after oral administration but before it reaches systemic circulation.
A: The blood-brain barrier limits CNS entry, not systemic circulation.
C: Renal clearance involves excretion, not metabolism before
absorption.
D: Bioequivalence relates to generic vs. brand drug comparisons.
3.
A 72-year-old patient is prescribed a benzodiazepine with a long half-life.
Over time, the drug accumulates, causing excessive sedation. This is most
likely due to:
A. Increased blood-brain barrier permeability
B. Reduced renal clearance due to age
C. Enzyme induction leading to faster metabolism
D. Decreased volume of distribution
, ✅ Correct Answer: B
Rationale: Elderly patients often have decreased renal and hepatic clearance,
leading to drug accumulation, especially for drugs with long half-lives.
A: The BBB doesn’t become more permeable with normal aging.
C: Enzyme induction would reduce, not increase, accumulation.
D: Volume of distribution reduction would not typically cause
accumulation in this way.
4.
A researcher wants to compare the bioavailability of two formulations of the
same antidepressant. Which pharmacokinetic parameter should they focus
on?
A. Peak plasma concentration (Cmax)
B. Half-life (t½)
C. Area under the plasma concentration-time curve (AUC)
D. Therapeutic index
✅ Correct Answer: C
Rationale: AUC directly measures drug exposure over time and is the gold
standard for comparing bioavailability between formulations.
A: Cmax reflects the rate of absorption, not total absorption.
B: Half-life describes elimination.
D: Therapeutic index measures safety margin, not bioavailability.
5.
Which of the following administration routes bypasses the first-pass
metabolism completely?
,(From Psychopharmacology: Drugs, the Brain, and Behavior, 4th Edition by
Meyer & Quenzer)
Each question has:
A clinical or research-oriented scenario
Answer choices (A–D)
✅ Correct Answer clearly labeled
Deep rationale for correct & incorrect options
Chapter 1 – Principles of Pharmacology: 28 Extra-Advanced MCQs
1.
A pharmaceutical company is developing a new antipsychotic medication.
During initial studies, they observe that increasing the dose beyond a certain
point no longer improves therapeutic effect but increases side effects. What
pharmacological principle does this illustrate?
A. First-pass metabolism
B. Dose-response curve plateau
C. Bioavailability limitation
D. Half-life extension
✅ Correct Answer: B
Rationale: The dose-response curve plateau represents the maximal efficacy
of a drug. Beyond this point, further increasing the dose does not increase
therapeutic effect but often increases adverse effects. This is a core concept
in pharmacodynamics.
A: First-pass metabolism involves drug metabolism in the liver before
reaching systemic circulation.
C: Bioavailability refers to the proportion of drug entering circulation,
not dose-effect limits.
, D: Half-life relates to drug elimination, not efficacy limits.
2.
A drug is administered orally, but only 40% reaches systemic circulation due
to extensive metabolism in the liver before entering the bloodstream. This
phenomenon is known as:
A. Blood-brain barrier filtration
B. First-pass effect
C. Renal clearance
D. Bioequivalence failure
✅ Correct Answer: B
Rationale: The first-pass effect refers to the metabolism of a drug in the liver
after oral administration but before it reaches systemic circulation.
A: The blood-brain barrier limits CNS entry, not systemic circulation.
C: Renal clearance involves excretion, not metabolism before
absorption.
D: Bioequivalence relates to generic vs. brand drug comparisons.
3.
A 72-year-old patient is prescribed a benzodiazepine with a long half-life.
Over time, the drug accumulates, causing excessive sedation. This is most
likely due to:
A. Increased blood-brain barrier permeability
B. Reduced renal clearance due to age
C. Enzyme induction leading to faster metabolism
D. Decreased volume of distribution
, ✅ Correct Answer: B
Rationale: Elderly patients often have decreased renal and hepatic clearance,
leading to drug accumulation, especially for drugs with long half-lives.
A: The BBB doesn’t become more permeable with normal aging.
C: Enzyme induction would reduce, not increase, accumulation.
D: Volume of distribution reduction would not typically cause
accumulation in this way.
4.
A researcher wants to compare the bioavailability of two formulations of the
same antidepressant. Which pharmacokinetic parameter should they focus
on?
A. Peak plasma concentration (Cmax)
B. Half-life (t½)
C. Area under the plasma concentration-time curve (AUC)
D. Therapeutic index
✅ Correct Answer: C
Rationale: AUC directly measures drug exposure over time and is the gold
standard for comparing bioavailability between formulations.
A: Cmax reflects the rate of absorption, not total absorption.
B: Half-life describes elimination.
D: Therapeutic index measures safety margin, not bioavailability.
5.
Which of the following administration routes bypasses the first-pass
metabolism completely?
